Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Alzheimer's Disease

• Publication date

  2010-09-10

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.3233/JAD-2010-100207PMID 21504133
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alzheimer's disease.

  2011cited by this paper
• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011cited by this paper
• Alzheimer's disease.

  2010cited by this paper
• Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

  2010cited by this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010cited by this paper
• Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

  2009cited by this paper
• Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease

  2009cited by this paper
• Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.

  2009cited by this paper
• Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.

  2009cited by this paper
• CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

  2009influential reference
• Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

  2009cited by this paper
• Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

  2009cited by this paper
• CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.

  2007cited by this paper
• Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

  2007cited by this paper
• Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

  2007cited by this paper
• Longitudinal changes of CSF biomarkers in memory clinic patients

  2007cited by this paper
• Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment

  2007cited by this paper
• Longitudinal stability of CSF biomarkers in Alzheimer's disease.

  2007cited by this paper
• Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide

  2007cited by this paper
• Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly

  2007cited by this paper
• Alzheimer's disease

  2006cited by this paper
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

  2006influential reference
• CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.

  2005cited by this paper
• Global prevalence of dementia: a Delphi consensus study

  2005cited by this paper
• Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

  2005cited by this paper
• Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

  2004cited by this paper
• Mild cognitive impairment as a diagnostic entity

  2004cited by this paper
• The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration

  2003cited by this paper
• Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds

  2003cited by this paper
• Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

  2002cited by this paper
• Research criteria for subcortical vascular dementia in clinical trials.

  2000cited by this paper
• Report of the second dementia with Lewy body international workshop

  1999cited by this paper
• Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

  1998cited by this paper
• Vascular dementia

  1993cited by this paper
• Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

  1988cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Index for rating diagnostic tests

  1950cited by this paper

• The German Dementia Registry (DEMREG): study protocol of a biomarker-based national registry for cognitive impairment and dementia

  2025influential citation
• A Comprehensive Study of Alzheimer’s Disease Biomarkers in Plasma and Cerebrospinal Fluid

  2025cites this paper
• Clinical utility of CSF Aβ38 in Japanese research and clinical cohorts

  2025cites this paper
• Systematic Review and Meta-Analysis on Heavy Metals and Trace Elements in Mild Cognitive Impairment.

  2025cites this paper
• Proteome profiling of cerebrospinal fluid using machine learning shows a unique protein signature associated with APOE4 genotype

  2024cites this paper
• Exercise to Counteract Alzheimer’s Disease: What Do Fluid Biomarkers Say?

  2024cites this paper
• Association of amyloid-beta with depression or depressive symptoms in older adults without dementia: a systematic review and meta-analysis

  2024cites this paper
• Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers

  2024influential citation
• Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy

  2024cites this paper
• Risk of cognitive decline progression is associated to increased blood‐brain‐barrier permeability: A longitudinal study in a memory unit clinical cohort

  2023cites this paper
• CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab

  2023cites this paper
• CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias

  2023cites this paper
• Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios

  2023cites this paper
• Cerebrospinal and Blood Biomarkers in Alzheimer’s Disease: Did Mild Cognitive Impairment Definition Affect Their Clinical Usefulness?

  2023cites this paper
• Clinical characteristics of patients with suspected Alzheimer’s disease within a CSF Aß-ratio grey zone

  2023cites this paper
• Statistical Parametric Mapping in Amyloid Positron Emission Tomography

  2022cites this paper
• Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia

  2022cites this paper
• Sleep duration and biomarkers of inflammation in African American and white participants with a parental history of Alzheimer's disease

  2022cites this paper
• Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

  2022cites this paper
• Alzheimer's disease: Pathological changes, recent treatment and future perspectives

  2022cites this paper
• A Systematic Review and Meta-Analysis of Cerebrospinal Fluid Amyloid and Tau Levels Identifies Mild Cognitive Impairment Patients Progressing to Alzheimer’s Disease

  2022influential citation
• Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217

  2022cites this paper
• Cerebrospinal Fluid Biomarkers in Patients With Unipolar Depression Compared With Healthy Control Individuals: A Systematic Review and Meta-analysis.

  2022cites this paper
• Markers of Cerebrovascular Injury, Inflammation, and Plasma Lipids Are Associated with Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in Cognitively Normal Persons

  2022cites this paper
• Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer's Disease.

  2021cites this paper
• Cerebral Amyloid Angiopathy in Amyloid-Positive Patients from a Memory Clinic Cohort

  2021influential citation
• Bias-generating factors in biofluid amyloid-β measurements for Alzheimer’s disease diagnosis

  2021cites this paper
• 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

  2021cites this paper
• Accelerated long-term forgetting in healthy older adults predicts cognitive decline over 1 year

  2020cites this paper
• Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

  2020cites this paper
• Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

  2020cites this paper
• Depressive disorders in the elderly and dementia: An update

  2020cites this paper
• CSF p-tau/Aβ42 ratio and brain FDG-PET may reliably detect MCI “imminent” converters to AD

  2020cites this paper
• Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

  2019cites this paper
• Contributions by the Brain Renin-Angiotensin System to Memory, Cognition, and Alzheimer’s Disease

  2019cites this paper
• Ruolo dei biomarcatori nella diagnostica liquorale della malattia di Alzheimer

  2019cites this paper
• Event related potentials (ERPs) and alpha waves in cognition, aging and selected dementias: A source of biomarkers and therapy

  2019influential citation
• Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays

  2019cites this paper
• The impact of pre-analytical variables on measuring CSF biomarkers for Alzheimer’s disease diagnosis: A review

  2019cites this paper
• Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases

  2019cites this paper
• Characterization of Inner Retinal Hyperreflective Alterations in Early Cognitive Impairment on Adaptive Optics Scanning Laser Ophthalmoscopy

  2019influential citation
• Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings.

  2019cites this paper
• CSF sAPPα and sAPPβ levels in Alzheimer’s Disease and Multiple Other Neurodegenerative Diseases: A Network Meta-Analysis

  2019cites this paper
• Mild Cognitive Impairment - concepts, cut-offs, and clinical relevance

  2019cites this paper
• Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study

  2018cites this paper
• Clinical Meaningfulness of Biomarker Endpoints in Alzheimer’s Disease Research

  2018cites this paper
• Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

  2018cites this paper
• Plasma β-amyloid1-42 reference values in cognitively normal subjects.

  2018cites this paper
• Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment

  2018cites this paper
• Biomarkeri u dijagnostici Alzheimerove bolesti

  2018cites this paper
• The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

  2018cites this paper
• Biomarkers for Alzheimer's disease: current status and prospects for the future

  2018cites this paper
• Proteomic-based Signature of Brain-related Proteins as Novel Candidate Biomarkers for Alzheimer’s Disease Diagnosis

  2018cites this paper
• Neuropsychological Testing and Machine Learning Distinguish Alzheimer’s Disease from Other Causes for Cognitive Impairment

  2017cites this paper
• Dissociating Normal Aging from Alzheimer’s Disease: A View from Cognitive Neuroscience

  2017cites this paper
• Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment

  2017cites this paper
• Platelet phosphorylated TDP-43: an exploratory study for a peripheral surrogate biomarker development for Alzheimer's disease

  2017cites this paper
• Cerebrospinal Fluid Amyloid-β 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer’s Disease

  2017cites this paper
• Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

  2017cites this paper
• Sugary Insights: A Biochemical Perspective

  2017cites this paper
• CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

  2017cites this paper
• Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.

  2016cites this paper
• Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias

  2016cites this paper
• Cerebrospinal Fluid Levels of Amyloid Beta 1–43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer’s Disease: A 2-Year Follow-Up Study

  2016cites this paper
• The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer’s Disease: Shortcomings in Prodromal Diagnosis

  2016cites this paper
• Biomarkers in Mild Stages of Alzheimer’s disease: Utility in clinical practice and their relation with nutritional and lifestyle factors

  2016cites this paper
• CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

  2016cites this paper
• Tau in Late-Life Depression: A Systematic Review and Meta-Analysis

  2016cites this paper
• Drug treatments in Alzheimer's disease.

  2016cites this paper
• Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia

  2016cites this paper
• Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a ‘European ADNI study’

  2016cites this paper
• Methods for the Specific Detection and Quantitation of Amyloid-β Oligomers in Cerebrospinal Fluid

  2016cites this paper
• How many biomarkers to discriminate neurodegenerative dementia?

  2015cites this paper
• Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer’s Disease in Pre-Dementia Subjects

  2015cites this paper
• Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis

  2015cites this paper
• Transferring Cut-off Values between Assays for Cerebrospinal Fluid Alzheimer’s Disease Biomarkers

  2015cites this paper
• Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics

  2015cites this paper
• Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

  2015cites this paper
• Plasma and cerebrospinal fluid amyloid-β levels in late-life depression: A systematic review and meta-analysis.

  2015cites this paper
• Featured Article CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study

  2015cites this paper
• CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large‐scale international multicenter study

  2015cites this paper
• Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease.

  2015cites this paper
• Low CSF concentration of mitochondrial DNA in preclinical Alzheimer ’ s disease . Running Head : mtDNA in preclinical Alzheimer ’ s disease CSF

  2015cites this paper
• Islet amyloid polypeptide (IAPP) in Type 2 diabetes and Alzheimer disease

  2015influential citation
• P50: A candidate ERP biomarker of prodromal Alzheimer's disease.

  2015influential citation
• Alzheimer disease Cerebrospinal Fluid biomarker in Cognitively Normal Subjects : Multicenter 1 Study 2

  2015cites this paper
• Alzheimer’s Disease and Other Neurodegenerative Disorders

  2015cites this paper
• Body fluid biomarkers in Alzheimer's disease.

  2015cites this paper
• Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia

  2015cites this paper
• Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

  2015cites this paper
• Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer's disease.

  2014cites this paper
• Accuracy of Cerebrospinal Fluid Aβ1-42 for Alzheimer's Disease Diagnosis: A Systematic Review and Meta-Analysis

  2014cites this paper
• Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

  2014cites this paper
• Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

  2014cites this paper
• The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean?

  2014cites this paper
• Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology

  2014cites this paper
• A systematic review of amyloid-β peptides as putative mediators of the association between affective disorders and Alzheimer׳s disease.

  2014cites this paper
• Improving CSF Biomarkers’ Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer’s Disease by Considering Different Confounding Factors: A Meta-Analysis

  2014cites this paper
• Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

  2014cites this paper
• Tau Monoclonal Antibody Generation Based on Humanized Yeast Models

  2014cites this paper